Episodios

  • ACT Brief: Digital Twins for Virtual Control Arms, Clinical Tech Stack Evolution, and Universal Flu Vaccine Advances

    ACT Brief: Digital Twins for Virtual Control Arms, Clinical Tech Stack Evolution, and Universal Flu Vaccine Advances
    Apr 3 2026
    In today's ACT Brief, we explore how digital twin technology creates reliable virtual control arms from historical data, what defines an effective clinical trial tech stack in complex studies, and emerging vaccine platforms advancing toward universal influenza protection.
    Más Menos
    2 m
  • ACT Brief: Platform vs. Bespoke Technology, Patient and Site Experience Design, and AI-Driven ADC Development

    ACT Brief: Platform vs. Bespoke Technology, Patient and Site Experience Design, and AI-Driven ADC Development
    Apr 2 2026
    In today's ACT Brief, we explore how to decide which trial complexities warrant core technology platforms versus custom configurations, how measuring patient and site experiences early identifies actionable solutions, and Daiichi Sankyo's collaboration with Tempus to improve ADC patient selection through AI.
    Más Menos
    2 m
  • ACT Brief: Intuitive Technology Design and Site Compliance, Vaccine Follow-Up Strategy Optimization, and AI-Driven Antibody Discovery

    ACT Brief: Intuitive Technology Design and Site Compliance, Vaccine Follow-Up Strategy Optimization, and AI-Driven Antibody Discovery
    Apr 1 2026
    In today's ACT Brief, we explore how user-friendly technology reduces errors and site workarounds, strategic approaches to combining traditional and real-world data collection for vaccine long-term follow-up, and Merck's collaboration with Infinimmune to accelerate antibody discovery using AI.
    Más Menos
    2 m
  • ACT Brief: Clinical Technology Implementation Priorities, Digital Supply Chain Integration, and AI Drug Discovery Scale

    ACT Brief: Clinical Technology Implementation Priorities, Digital Supply Chain Integration, and AI Drug Discovery Scale
    Mar 31 2026
    In today's ACT Brief, we examine the three converging technology priorities reshaping trial execution in 2026, why sponsors must integrate digital and physical supply chains operationally, and Eli Lilly's multi-billion dollar AI drug discovery collaboration with Insilico.
    Más Menos
    2 m
  • ACT Brief: Clinical Workflow User Experience, Sample Integrity and Logistics, and FDA's Unified Adverse Event System

    ACT Brief: Clinical Workflow User Experience, Sample Integrity and Logistics, and FDA's Unified Adverse Event System
    Mar 30 2026
    In today's ACT Brief, we examine why eClinical platforms must prioritize user workflows over data flow, how digitizing sample tracking prevents integrity failures in transit, and the FDA's consolidated adverse event monitoring system enabling real-time safety signal detection.
    Más Menos
    2 m
  • ACT Brief: CRO Selection as Incentive Design, Integrated Tech Stack Strategy, and Pricing Disruption in Pharma

    ACT Brief: CRO Selection as Incentive Design, Integrated Tech Stack Strategy, and Pricing Disruption in Pharma
    Mar 27 2026
    In today's ACT Brief, we examine how game theory principles can improve CRO and vendor selection through ecosystem alignment, why clinical technology platforms must be purpose-built and fully integrated, and how pricing pressures and regulatory changes are reshaping pharmaceutical R&D investment.
    Más Menos
    2 m
  • ACT Brief: Behavioral Science and Recruitment Design, Community Engagement in Trials, and Big Pharma's Rare Disease Interest

    ACT Brief: Behavioral Science and Recruitment Design, Community Engagement in Trials, and Big Pharma's Rare Disease Interest
    Mar 26 2026
    : In today's ACT Brief, we examine how behavioral science applied during trial design and startup can identify recruitment barriers early, the importance of authentic community engagement over traditional outreach, and how large pharmaceutical companies are increasingly investing in rare disease development.
    Más Menos
    2 m
  • ACT Brief: Thermo Fisher Acquires Clario, Wearables and AI Integration, and Somatic Genomics for IBD

    ACT Brief: Thermo Fisher Acquires Clario, Wearables and AI Integration, and Somatic Genomics for IBD
    Mar 25 2026
    In today's ACT Brief, we examine Thermo Fisher's acquisition of Clario to expand clinical trial data infrastructure, how wearable devices and AI are reshaping patient monitoring workflows, and a collaboration between Merck and Quotient using somatic genomics to identify IBD drug targets.
    Más Menos
    2 m